On June 26, Novo Nordisk announcedPhase III of Ocedurenone for the Treatment of Hypertension with Chronic Kidney Disease (CKD)CLARION-CKD Study Did Not Meet Primary Endpoint and Stated2024YearThis will generate approximately DKK 5.7 billion (approximately USD 828 million) inImpairmentLoss.Ocedurenone is an oral small-molecule non-steroidal mineralocorticoid receptor (nsMR) antagonist acquired by Novo Nordisk for $1.3 billion from KBP Biosciences., which has a long half-life and high MR affinity.CLARION-CKD Study is a multicenter, randomized, double-blind, placebo-controlled clinical trial (n=600) that evaluated the efficacy and safety of Ocedurenone in patients with uncontrolled hypertension (140mmHg ≤ systolic blood pressure < 180mmHg) and moderate to severe (Stage IIIb/IV) CKD. The primary endpoint was the change in systolic blood pressure from baseline at Week 12.The Independent Data Monitoring Committee concluded, based on the interim analysis results, that the trial met the pre-specified futility criteria, meaning the study did not achieve its primary endpoint. Therefore, Novo Nordisk decided to terminate the CLARION-CKD study.Novo Nordisk expects this move to reduce the projected operating profit growth for Q1 2024 by 6%.In addition,Novo NordiskCorrectInEvaluationOFurther applications of cedurenone in other indicationsDevelopment Plan。Disclaimer:
The content of the article is for reference only and does not constitute investment advice. Investors who take action based on this information bear their own risks. The article maintains a neutral stance regarding any statements or viewpoints expressed and does not provide any explicit or implicit guarantees concerning the accuracy, reliability, or completeness of the content. Readers are advised to use the information for reference only and assume full responsibility for their actions. The various articles published by this public account focus on sharing; if there is any infringement, please contact us, and we will delete them.
Booths for the Class of 2024 are now available for booking!
(Sponsorship forms include but are not limited toSpeaking slots, exhibition booths, color pages in the conference proceedings, dinner sponsorship, promotional conference materials, etc.)
Scan to consult immediately!
Phone: 13816031174 (Same as WeChat)
Email: marketing@truesaw.com
Click here"Read the full text"Consult for more exciting content!
